Table 2.
Linear regression analyses of C-reactive protein and plasma albumin levels as dependent variables and patient characteristics as explanatory variables on date of diagnosis of acute myeloid leukaemia (AML), based on 491 specimens with both CRP and PA measured
| Patient characteristics on date of diagnosis of AML | C-reactive protein | Plasma albumin | ||
|---|---|---|---|---|
| Crude analysis | Adjusted analysisa | Crude analysis | Adjusted analysisa | |
| Sex | ||||
| Females | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Males | 3.80 (−10.5/18.1)b | 1.78 (− 12.1/15.7) | −1.00 (− 2.10/0.10) | − 1.01 (− 2.02/0.00) |
| Age group, years | ||||
| 15–64 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 65–80 | 5.76 (−9.97/21.5) | 1.29 (−14.9/17.5) | −2.01 (− 3.18/−0.84)c | −1.15 (− 2.32/0.02) |
| + 80 | −3.60 (− 24.1/16.9) | − 16.5 (− 37.6/4.57) | −4.46 (−5.99/− 2.94) | − 2.76 (− 4.28/− 1.24) |
| Body mass index (kg/m^2) | ||||
| < 18.5 | −15.3 (−60.4/29.9) | −19.1 (−63.4/25.1) | −3.32 (−6.78/0.14) | − 2.54 (− 5.73/0.65) |
| 18.5–24.9 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 25–29.9 | 4.12 (− 14.0/22.2) | 4.36 (−13.5/22.2) | 0.31 (− 1.07/1.70) | 0.08 (− 1.21/1.37) |
| ≥ 30 | −8.81 (−30.6/13.0) | −6.27 (− 27.6/15.0) | 1.33 (− 0.34/3.00) | 0.74 (− 0.80/2.28) |
| Unknown | 30.6 (10.7/50.6) | 17.3 (−2.84/37.4) | − 2.20 (− 3.72/− 0.67) | − 0.26 (− 1.71/1.20) |
| Charlson comorbidity index | ||||
| 0 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 1–2 | 5.68 (− 10.3/21.7) | 5.05 (− 11.2/21.3) | − 1.23 (− 2.46/0.01) | − 0.33 (− 1.50/0.84) |
| > 2 | 8.07 (− 13.5/29.6) | −2.91 (− 24.7/18.9) | −1.89 (− 3.54/− 0.25) | 0.35 (− 1.23/1.92) |
| WHO performance status | ||||
| 0 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 1 | 12.4 (− 6.02/30.8) | 12.3 (− 6.40/31.0) | −2.38 (− 3.73/− 1.03) | −2.18 (− 3.53/− 0.84) |
| 2 | 36.1 (13.6/58.6) | 36.7 (13.1/60.3) | −4.98 (− 6.63/− 3.34) | − 4.21 (− 5.91/− 2.51) |
| 3/4 | 74.9 (51.2/98.6) | 68.1 (42.2/94.0) | −8.41 (− 10.1/− 6.67) | − 7.54 (− 9.41/− 5.67) |
| Neutrophil granulocytes (10^9/L) | ||||
| < 0.5 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 0.5–0.9 | 10.7 (− 13.0/34.5) | 5.01 (− 18.0/28.1) | − 0.19 (− 2.00/1.62) | 0.65 (−1.02/2.31) |
| 1.0–1.4 | 15.1 (−14.2/44.5) | 1.25 (− 27.2/29.7) | − 0.55(− 2.79/1.68) | 0.55 (− 1.51/2.60) |
| ≥ 1.5 | 17.9 (0.37/35.5) | 10.1 (−7.22/27.3) | −2.16 (− 3.50/− 0.82) | −1.10 (− 2.34/0.15) |
| Unknown | 11.7 (− 11.8/35.2) | 1.96 (− 20.9/24.9) | −2.73 (− 4.52/− 0.94) | −2.00 (− 3.65/− 0.34) |
| Blast percentage, bone marrow biopsy | ||||
| 0–19 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 20–39 | 18.1 (− 61.1/97.2) | 31.1 (− 46.3/109) | 3.71 (−2.48/9.90) | 2.49 (− 3.10/8.08) |
| 40–59 | 21.9 (− 57.8/102) | 31.9 (− 46.0/110) | 2.91 (− 3.32/9.14) | 1.65 (− 3.98/7.28) |
| 60–79 | 31.0 (− 48.7/111) | 40.9 (− 36.9/119) | 3.73 (− 2.51/9.96) | 2.18 (− 3.43/7.80) |
| 80–100 | 52.4 (− 27.5/132) | 63.0 (− 15.2/141) | 3.58 (− 2.66/9.83) | 2.05 (− 3.60/7.69) |
| Unknown | 62.1 (−21.2/145) | 55.6 (− 25.4/137) | 2.28 (− 4.22/8.79) | 2.96 (− 2.89/8.81) |
aAdjusted for all covariates in Table 2
bCoefficient (95% confidence interval)
cBold types: statistically significant (p < 0.05)